Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study [Abstract LBP-522] | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study [Abstract LBP-522]

Rockstroh J, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer A, et al. Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study [Abstract LBP-522]. In The International Liver Congress. EASL [Internet]. 2017. http://dx.doi.org/10.1016/S0168-8278(17)30467-1

Publication Type:

Conference Paper

Authors:

Rockstroh, J.; Lacombe, K.; Viani, R.M.; Orkin, C.; Wyles, D.; Luetkemeyer, A.; Soto-Malave, R.; Flisiak, R.; Bhagani, S.; Sherman, K.E.; Shimonova, T.; Ruane, P.; Sasadeusz, J.; Slim, J.; Zhang, Z.; Ng, T.I.; Trinh, R.; Sulkowski, M.

Source:

The International Liver Congress. EASL (2017)

URL:

http://dx.doi.org/10.1016/S0168-8278(17)30467-1

Notes:

doi: 10.1016/S0168-8278(17)30467-1

Cited On:

External Third-party Web Link:

https://www.journal-of-hepatology.eu/article/S0168-8278(17)30467-1/pdf

Export Citation:

RIS Format

Top